Report
Expert Corporate Governance Service (ECGS)
EUR 1000.00 For Business Accounts Only

Amplifon – AGM 24 April 2020

In item 3.a, shareholders are called to a binding vote on the remuneration policy. Aggregate variable remuneration is capped at 336% of the CEO's fixed remuneration, slightly above ECGS' guidelines of 300%, and, in our opinion, it is adequately structured to realize and alignment of interests with shareholders in the long term. However, we note that the variable-to-fixed remuneration decreased in the last years only because the CEO's base salary significantly increased (+27.2% in 2019, +5.8% in 2018 and +51.6% in 2017) without providing any justifications to shareholders. Also taking into account that severance payments (30 months of cash remuneration) are not in accordance with Italian guidelines of 2 years of remuneration, we recommend opposition.

 

Due to our concerns over the excessive discretionary powers of the Board in increasing the CEO's fixed remuneration, we also recommend shareholders to oppose the remuneration paid in 2019 (advisory vote in item 3.b).

 

In item 4, the Board of Directors asks for the authorization to buy-back shares. While ECGS acknowledges that the Company is currently well capitalised, and the terms of the authorization are in line with its guidelines, it considers that the potential impact of the Covid-19 induced crisis is not yet known. Therefore, we consider that it is not appropriate to seek approval for a new buyback programme. Furthermore, in our opinion, the proposed authorization is not consistent with the Company's decision to suspend the payment of dividends in 2020 (in item 1.b). Therefore, we recommend opposition.

Underlying
Amplifon S.p.A.

Amplifon is multinational company engaged in the ddistribution, fitting, adaptation and personalization of hearing systems (hearing aids) designed to meet the needs of those suffering from hearing disabilities. Co. is also engaged in the sale of accessories such as batteries, consumables and spare parts, as well as in the distribution of biomedical devices. Co. is active in 20 different countries: Italy, France, Germany, Switzerland, The Netherlands, Belgium, Luxembourg, the U.K., Ireland, Spain, Portugal, Hungary, Turkey, the U.S., Canada, Australia, New Zealand, India, Egypt, and in Poland.

Provider
Proxinvest
Proxinvest

Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Analysts
Expert Corporate Governance Service (ECGS)

Other Reports on these Companies
Other Reports from Proxinvest

ResearchPool Subscriptions

Get the most out of your insights

Get in touch